Monocional Antibodies into the '90s: The All-Purpose Tool

Carlsson, Roland; Glad, Cristina; Borrebaeck, Carl

doi:10.1038/nbt0689-567

Cited by 17 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ever since the inception of hybridoma technology there has been an enormous increase in the use of antibodies as reagents. In biological and medical research, antibodies are currently used to diagnose, treat, and even vaccinate against a wide range of diseases (Carlsson and Glad, 1989). There is also a potential use of antibodies as tailor-made, enzymelike catalysts for chemical reactions (Green and Tawfik, 1989).…”

Section: Introductionmentioning

confidence: 99%

Growth, Metabolic, And Antibody Production Kinetics Of Hybridoma Cell Culture: 1. Analysis Of Data From Controlled Batch Reactors

Öztürk

Palsson

1991

Biotechnology Progress

View full text Add to dashboard Cite

A mouse-mouse hybridoma cell line (167.4G5.3) was cultivated in a 1.5-L stirred-tank bioreactor under constant pH and dissolved oxygen concentration. The transient kinetics of cell growth, metabolism, and antibody production were followed by biochemical and flow cytometric methods. The cell-specific kinetic parameters (growth and metabolic rates) as well as cell size were constant throughout the exponential phase. Intracellular protein and RNA content followed a similar trend. Cell growth stopped when the glutamine in the medium was depleted. Glucose could not substitute for glutamine, as glucose consumption ceased after glutamine depletion. Ammonia and lactate production followed closely glutamine and glucose consumption, respectively. Alanine, glutamate, serine, and glycine were produced but other amino acids were consumed. The cells are estimated to obtain about 45% of the total energy from glycolysis, with the balance of the metabolic energy provided by oxidative phosphorylation. The antibody was produced at a constant rate in both the exponential and decline phases of growth. The intracellular antibody content of the cells remained relatively constant during the exponential phase of growth and decreased slightly afterwards.

show abstract

Section: Introductionmentioning

confidence: 99%

Growth, Metabolic, And Antibody Production Kinetics Of Hybridoma Cell Culture: 1. Analysis Of Data From Controlled Batch Reactors

Öztürk

Palsson

1991

Biotechnology Progress

View full text Add to dashboard Cite

show abstract

“…Hybridoma technology has made it possible to produce large amounts of monoclonal antibodies in vitro and thus has extended their use to many applications. As well as serving as a detection tool for molecular biologists, antibody specificity has been exploited in such areas as affinity chromatography, antibody-mediated immunotherapy in the treatment of tumors and infectious diseases, and the use of antibodies as vaccines and even as enzymes that can catalyze chemical transformation of target molecules (Carlsson and Glad, 1989;Leist et al, 1990;Janda, 1990;Schultz, 1989).…”

Section: Introductionmentioning

confidence: 99%

Manipulation of Heterogeneous Hybridoma Cultures for Overproduction of Monoclonal Antibodies

McKinney

Dilwith

Belfort

1991

Biotechnology Progress

View full text Add to dashboard Cite

In searching for ways to manipulate heterogeneous hybridoma cell cultures (ATCC HB124) to obtain increased production of monoclonal antibodies (IgG2a), we have selected for a higher secreting but slower growing subpopulation using the level of fluorescent surface-associated antibodies and a fluorescence-activated cell sorter. Cell surface fluorescence was found to be correlated with specific antibody secretion rate over the short term but not with intracellular antibody content. Also, the specific secretion rate of a heterogeneous population of hybridoma cells grown in batch culture has been shown to be inversely correlated with an increase in either the initial cell concentration or the medium antibody concentration. Several experiments suggest that an upper limit exists for medium antibody concentration, above which antibody is degraded at the same rate at which it is produced. Should other cell lines behave similarly, strategies for overproduction of monoclonal antibodies suggested herein could be profitably used in industry.

show abstract

“…Chimeric antibodies with mouse variable and human constant domains have been constructed by linking together the genes encoding each domain (17). However, reshaped "humanized" monoclonal antibodies may loose their high affinity due to the reshaping, indicating that the hypervariable regions are not the only denominator which determine the affinity for a certain antigen (18,19). Reshaping or "humanizing" is therefore still not an easy or general approach.…”

Section: Prospects For Monoclonal Antibodies In the Diagnosis And Trementioning

confidence: 98%

Prospects for monoclonal antibodies in the diagnosis and treatment of bacterial infections

Verhoef¹,

Torensma²

1990

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

Monocional Antibodies into the '90s: The All-Purpose Tool

Cited by 17 publications

References 47 publications

Growth, Metabolic, And Antibody Production Kinetics Of Hybridoma Cell Culture: 1. Analysis Of Data From Controlled Batch Reactors

Growth, Metabolic, And Antibody Production Kinetics Of Hybridoma Cell Culture: 1. Analysis Of Data From Controlled Batch Reactors

Manipulation of Heterogeneous Hybridoma Cultures for Overproduction of Monoclonal Antibodies

Prospects for monoclonal antibodies in the diagnosis and treatment of bacterial infections

Contact Info

Product

Resources

About